HIV

US appeal in high-stakes Gilead patent case garners support from patient advocates
US appeal in high-stakes Gilead patent case garners support from patient advocates
Fierce Pharma
Gilead Sciences
HIV
patents
legal
DOJ
Truvada
Flag link:
Gilead, Teva reach 11th-hour settlements with some groups in HIV antitrust case
Gilead, Teva reach 11th-hour settlements with some groups in HIV antitrust case
Fierce Pharma
Gilead Sciences
Teva Pharmaceutical
HIV
legal
antitrust
Flag link:
After years of litigation, Gilead and Teva's HIV antitrust trial kicks off in California
After years of litigation, Gilead and Teva's HIV antitrust trial kicks off in California
Fierce Pharma
Gilead Sciences
Teva Pharmaceutical
legal
HIV
antitrust
Flag link:
Gilead notches trial win in high-stakes HIV patent case against US government
Gilead notches trial win in high-stakes HIV patent case against US government
Fierce Pharma
Gilead Sciences
Truvada
HIV
Descovy
legal
patents
Flag link:
Vir Biotechnology awarded $10 million grant by Bill & Melinda Gates Foundation to develop HIV vaccine
Vir Biotechnology awarded $10 million grant by Bill & Melinda Gates Foundation to develop HIV vaccine
Biopharma Reporter
Vir Biotechnology
Gates Foundation
vaccines
HIV
Flag link:
Gilead gets big $175m judgment in HIV fraud case
Gilead gets big $175m judgment in HIV fraud case
Pharmaphorum
Gilead Sciences
HIV
fraud
legal
reimbursement
Flag link:
CROI 2023 – GSK and Gilead’s long-acting HIV battle intensifies
CROI 2023 – GSK and Gilead’s long-acting HIV battle intensifies
EP Vantage
GSK
Gilead Sciences
CROI
Cabenuva
HIV
Flag link:
GSK's ViiV says study shows its long-acting HIV shot as effective as Gilead's daily pill
GSK's ViiV says study shows its long-acting HIV shot as effective as Gilead's daily pill
Yahoo/Reuters
GSK
HIV
ViiV Healthcare
Gilead Sciences
Cabenuva
Biktarvy
Flag link:
Gilead Sciences reports positive data from HIV therapy trial
Gilead Sciences reports positive data from HIV therapy trial
Clinical Trials Arena
Gilead Sciences
lenacapavir
HIV
clinical trials
Flag link:
Gilead, Teva and J&J's HIV antitrust case inches closer to trial as judge keeps most claims on the table
Gilead, Teva and J&J's HIV antitrust case inches closer to trial as judge keeps most claims on the table
Fierce Pharma
Gilead Sciences
legal
HIV
antitrust
Teva Pharmaceutical
JNJ
Flag link:
Oncology, HIV sales lift Gilead’s revenues by 2%
Oncology, HIV sales lift Gilead’s revenues by 2%
Medical Marketing and Media
Gilead Sciences
earnings
HIV
oncology
hepatitis C
Flag link:
J&J packs up HIV vaccine after failing phase 3 trial
J&J packs up HIV vaccine after failing phase 3 trial
Fierce Biotech
JNJ
vaccines
HIV
HIV vaccines
clinical trials
Flag link:
FDA approves drugs from Gilead, Roche, TG Therapeutics to close 2022
FDA approves drugs from Gilead, Roche, TG Therapeutics to close 2022
BioPharma Dive
FDA
drug approvals
HIV
lymphoma
multiple sclerosis
Gilead Sciences
Roche
TG Therapeutics
Flag link:
Gilead goes long-acting in HIV
Gilead goes long-acting in HIV
EP Vantage
Gilead Sciences
lenacapavir
HIV
FDA
Flag link:
Federal claims court rules in favor of Gilead in CDC Truvada patent case
Federal claims court rules in favor of Gilead in CDC Truvada patent case
Endpoints
Gilead Sciences
Truvada
PrEP
HIV
CDC
patents
Flag link:
GSK's ViiV gives early look at HIV broadly neutralizing antibody's power, eyes long-acting combo trial
GSK's ViiV gives early look at HIV broadly neutralizing antibody's power, eyes long-acting combo trial
Fierce Biotech
GSK
ViiV
bNab
N6LS
HIV
Flag link:
4 Biotech Stocks With Huge Incoming Catalysts
4 Biotech Stocks With Huge Incoming Catalysts
Motley Fool
FDA
Biogen
Eisai
Alzheimer's disease
Gilead Sciences
HIV
Mirati Therapeutics
lung cancer
lecanemab
lenacapavir
adagrasib
Flag link:
Gilead targets 'large-scale' HIV drugs counterfeiting scheme as judge orders asset freeze
Gilead targets 'large-scale' HIV drugs counterfeiting scheme as judge orders asset freeze
Fierce Pharma
Gilead Sciences
HIV
drug counterfeiting
legal
Flag link:
GSK, still early in US launch, licenses long-acting HIV PrEP drug Apretude to patent pool for poorer nations
GSK, still early in US launch, licenses long-acting HIV PrEP drug Apretude to patent pool for poorer nations
Fierce Pharma
GSK
HIV
PrEP
Apretude
Medicines Patent Pool
Flag link:
AIDS 2022 preview – Gilead shoots for an HIV cure
AIDS 2022 preview – Gilead shoots for an HIV cure
EP Vantage
Gilead Sciences
HIV
AIDS
Flag link:

Pages